Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn’s disease

Figures & data

Figure 1. Flow chart of patients.

Table 1. Baseline patient characteristics.

		n = 59
Age^a	Median (IQR)	38 (26–52)
Sex, female	n (%)	38 (64)
Smoking	n (%)	13 (22)
Disease duration, years	Median (IQR)	12.8 (8.1–18.1)
Age at diagnose
A1 < 16 yr	n (%)	16 (27)
A2 17–39 yr	n (%)	39 (66)
A3 ≥ 40 yr	n (%)	4 (7)
Disease location^a
L1 ileal	n (%)	8 (14)
L2 colonic	n (%)	6 (10)
L3 ileocolonic	n (%)	45 (76)
+ L4 upper GI disease	n (%)	7 (12)
Disease behaviour^a
B1 non stricturing, non-penetrating	n (%)	24 (40)
B2 stricturing	n (%)	28 (48)
B3 penetrating	n (%)	7 (12)
+Perianal disease	n (%)	13 (22)
Prior intestinal resections	n (%)	37 (63)
Prior Anti-TNFα exposure
naive	n (%)	0 (0)
1	n (%)	7 (12)
≥2	n (%)	55 (88)
Prior vedolizumab exposure	n (%)	30 (51)
Disease activity
Harvey Bradshaw Index, n = 52	Median (IQR)	9.5 (5.0–13.0)
C- Reactive Protein, mg/L, n = 52	Median (IQR)	5.9 (1.5–37.5)
Faecal calprotectin, µg/g, n = 52	Median (IQR)	604 (331–1297)
Simple Endoscopic Score for CD, n = 23	Median (IQR)	11 (9–16)
Rutgeers Score, n = 30	Median (IQR)	3 (2–4)
Concomitant medication
Corticosteroids	n (%)	34 (58)
Immunomodulators	n (%)	8 (14)

N: numbers of patients; CD: Crohn’s disease; L: location; B: behavior; E: extent; TNFα: tumor necrosis factor alpha.

^aAt inclusion.

Figure 2. Serial median HBI during UST induction.

Figure 3. Serial fecal calprotectin during UST induction.

Figure 4. Serial fecal calprotectin during UST induction, specified for patients with and without endoscopic response.